Guberina, Maja
Eberhardt, Wilfried
Stuschke, Martin
Gauler, Thomas
Aigner, Clemens
Schuler, Martin
Stamatis, Georgios
Theegarten, Dirk
Jentzen, Walter
Herrmann, Ken
Pöttgen, Christoph http://orcid.org/0000-0002-9224-9318
Funding for this research was provided by:
Deutsche Krebshilfe (70-3070-Eb)
Article History
Received: 21 October 2018
Accepted: 10 January 2019
First Online: 1 February 2019
Compliance with ethical standards
:
: W. Eberhardt received honoraria from Eli Lilly, Boehringer Ingelheim, Pfizer, Novartis, Roche, Merck, Bristol-Myers Squibb, Amgen, GlaxoSmithKline, Aestellas, Bayer, Teva, Merck Serono, Daichi Sankyo and Hexal, and is a consultand or advisor to Eli Lilly, Boehringer Ingelheim, Novartis, Pfizer, Roche, Merck, Bristol-Myers Squibb, Aestellas, Bayer, Teva, Daichi Sankyo. Research Funding and Eli Lilly (Inst).T. Gauler received Honoraria from Eli Lilly, Boehringer Ingelheim, Merck Serono, Novartis, Roche, Pfizer, Bayer, MSD Oncology, Bristol-Myers Squibb, Symphogen and GlaxoSmithKline, is a consultand or advisor to MSD Oncology, Merck Serono, Novartis, and Eli Lilly, and received travel, accommodation and other expenses from Boehringer Ingelheim and Merck Serono.M. Schuler received honoraria from Alexion Pharmaceuticals, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Eli Lilly, Novartis and Pfizer, is a consultant or advisor to AstraZeneca, Boehringer Ingelheim, Celgene, Bristol-Myers Squibb, Novartis, IQWiG and Eli Lilly, and received research funding from Boehringer Ingelheim (Inst), Novartis (Inst) and Bristol-Myers Squibb (Inst). Patents, Royalties, Other intellectual property: patents (University Hospital Essen).D. Theegarten is an advisory board member of E. Lilly.C. Pöttgen received honoraria from Roche Pharma and Boehringer Ingelheim (speakers bureau).All other authors declare no conflicts of interest.
: All procedures performed were in accordance with the ethical standards of the institutional research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments. This secondary analysis was approved by the lead ethics committee of the Medical Faculty of the University Duisburg-Essen in September 2016.